Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 305-729-0 | CAS number: 95009-01-1
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Aug 22, 2016 - Nov 24, 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- OECD 402:1987
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- Sodium [4-[[dihydroxy[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]benzenesulphonato(3-)]cuprate(1-)
- EC Number:
- 305-729-0
- EC Name:
- Sodium [4-[[dihydroxy[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]benzenesulphonato(3-)]cuprate(1-)
- Cas Number:
- 95009-01-1
- Molecular formula:
- C18H9CuN6O10S.Na
- IUPAC Name:
- Reaction products of diazotized 4-aminobenzenesulfonic acid coupled with resorcinol subsequently coupled with diazotised 2-amino-4,6-dinitrophenol, copper (2+) complexes, sodium salts
- Test material form:
- solid: particulate/powder
- Details on test material:
- - Name of test material (as cited in study report): Everlan SL65
- Substance type: Powder
- Composition of test material, percentage of components: 71.19%
- Lot/batch No.: 3010
- Storage condition of test material: Ambient
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: BioLASCO Taiwan Co. Ltd.
- Age at study initiation: about 7 weeks old
- Housing: Male and female rats were fed, respectively. Two rats per cage in an autoclaved polyethylene cage.
- Acclimation period: 7 Days
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 55 ± 15%
- Photoperiod: 12 hrs dark / 12 hrs light
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- olive oil
- Duration of exposure:
- 24 hours
- Doses:
- 2,000 mg/kg B.W. for the limited test
- No. of animals per sex per dose:
- for control group: six male and six female
for test group: six male and six female - Control animals:
- yes, concurrent vehicle
Results and discussion
- Preliminary study:
- In the pilot study, fixed doses of 50, 200, 1,000 and 2,000 mg/kg B.W. are used to select the treatment dose. The dose of Everlan SL65 didn't cause death in the rat, a limit test is conducted with the dose of 2,000 mg/kg B.W.
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- no indication of skin irritation up to the relevant limit dose level
Any other information on results incl. tables
Table 1. Body weight of the rats in the study period
Group |
Animal I.D. |
Dosing volume (mL) |
Body weight (g) |
Weight chenges(g) |
|
Day 1 |
Day 14 |
||||
Control |
01M |
0.6 |
277.8 |
359.1 |
+81.3 |
02M |
0.6 |
286.5 |
361.6 |
+75.1 |
|
03M |
0.6 |
279.5 |
351.6 |
+72.1 |
|
04M |
0.5 |
265.6 |
338.7 |
+73.1 |
|
05M |
0.6 |
286.5 |
369.7 |
+83.2 |
|
06M |
0.6 |
285.9 |
365.3 |
+79.4 |
|
Test |
07M |
0.5 |
262.6 |
369.5 |
+106.9 |
08M |
0.6 |
279.6 |
363.8 |
+84.2 |
|
09M |
0.5 |
271.1 |
346.2 |
+75.1 |
|
10M |
0.6 |
275.9 |
356.4 |
+80.5 |
|
11M |
0.5 |
269.3 |
337.0 |
+67.7 |
|
12M |
0.6 |
305.8 |
388.4 |
+82.6 |
|
Control |
13F |
0.4 |
204.3 |
246.1 |
+41.8 |
14F |
0.4 |
200.9 |
264.8 |
+63.9 |
|
15F |
0.4 |
206.2 |
239.3 |
+33.1 |
|
16F |
0.4 |
219.3 |
268.6 |
+49.3 |
|
17F |
0.4 |
215.6 |
254.9 |
+39.3 |
|
18F |
0.4 |
220.8 |
252.9 |
+32.1 |
|
Test |
19F |
0.4 |
200.1 |
236.4 |
+36.3 |
20F |
0.4 |
209.5 |
242.5 |
+33.0 |
|
21F |
0.4 |
213.5 |
248.9 |
+35.4 |
|
22F |
0.4 |
220.5 |
252.0 |
+31.5 |
|
23F |
0.4 |
222.0 |
263.6 |
+41.6 |
|
24F |
0.4 |
214.1 |
244.7 |
+30.6 |
|
Table 2. Clinical observation of the rats
Animal I.D. |
Clinical sign observation |
||||||||||||||
30 mins |
4 hours |
D2 |
D3 |
D4 |
D5 |
D6 |
D7 |
D8 |
D9 |
D10 |
D11 |
D12 |
D13 |
D14 |
|
01M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
02M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
03M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
04M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
05M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
06M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
07M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
08M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
09M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
10M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
11M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
12M |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
13F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
14F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
15F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
16F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
17F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
18F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
19F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
20F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
21F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
22F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
23F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
24F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
DX: Day X in the study period
N: Normal
Table 3. Results of gross necropsy examination
Animal I.D. |
Dose |
Gross lesion |
01M |
─ |
No significant lesion founded |
02M |
No significant lesion founded |
|
03M |
No significant lesion founded |
|
04M |
No significant lesion founded |
|
05M |
No significant lesion founded |
|
06M |
No significant lesion founded |
|
07M |
2000 mg/kg B.W. |
No significant lesion founded |
08M |
No significant lesion founded |
|
09M |
No significant lesion founded |
|
10M |
No significant lesion founded |
|
11M |
No significant lesion founded |
|
12M |
No significant lesion founded |
|
13F |
─ |
No significant lesion founded |
14F |
No significant lesion founded |
|
15F |
No significant lesion founded |
|
16F |
No significant lesion founded |
|
17F |
No significant lesion founded |
|
18F |
No significant lesion founded |
|
19F |
2000 mg/kg B.W. |
No significant lesion founded |
20F |
No significant lesion founded |
|
21F |
No significant lesion founded |
|
22F |
No significant lesion founded |
|
23F |
No significant lesion founded |
|
24F |
No significant lesion founded |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to OECD 402 test method, the LD50 of Everlan SL65 was greater than 2000 mg/kg B.W.. Therefore, Everlan SL65 was Category 5 based on GHS criteria.
- Executive summary:
This test using the procedures outlined in the SuperLab for M62-151100100001EN which is based on the SOP (SOPP-342) for the OECD 402 and OECD 402 (OECD, 1987). Six male and six femaleSprague-Dawley rats for each group were used in limit test. For Test group, 12 Sprague-Dawley ratsweredermally dosed with 2000 mg/kg B.W. of Everlan SL65. All animals tolerated the test article well with increasing body weights and no mortality or gross lesions findings reported. In absence of mortality or other significant clinical signs of toxicity, LD50 of Everlan SL65 was greater than 2,000 mg/kg B.W..
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
